Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz Sells 39,751 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz sold 39,751 shares of the business’s stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $50.07, for a total value of $1,990,332.57. Following the sale, the chief executive officer now owns 2,147,309 shares of the company’s stock, valued at approximately $107,515,761.63. This represents a 1.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Amirali Talasaz also recently made the following trade(s):

• On Monday, June 9th, Amirali Talasaz sold 77,853 shares of Guardant Health stock. The stock was sold at an average price of $50.09, for a total transaction of $3,899,656.77.
• On Thursday, June 5th, Amirali Talasaz sold 1,680 shares of Guardant Health stock. The shares were sold at an average price of $50.00, for a total transaction of $84,000.00.
• On Thursday, May 1st, Amirali Talasaz sold 106,784 shares of Guardant Health stock. The stock was sold at an average price of $49.01, for a total transaction of $5,233,483.84.

Guardant Health Trading Up 3.1%

Shares of GH stock opened at $49.53 on Tuesday. The stock has a market capitalization of $6.14 billion, a price-to-earnings ratio of -13.91 and a beta of 1.37. Guardant Health, Inc. has a 12-month low of $20.14 and a 12-month high of $52.92. The stock’s 50-day moving average price is $43.05 and its 200-day moving average price is $41.25.

Guardant Health (NASDAQ:GH) last posted its earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $203.47 million during the quarter, compared to analyst estimates of $189.91 million. During the same period last year, the firm posted ($0.46) earnings per share. Guardant Health’s revenue for the quarter was up 20.8% compared to the same quarter last year. As a group, research analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GH has been the subject of several analyst reports. Mizuho started coverage on Guardant Health in a research note on Thursday, April 10th. They issued an “outperform” rating and a $55.00 price objective for the company. Barclays boosted their price target on Guardant Health from $55.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, May 1st. Morgan Stanley upped their price target on Guardant Health from $42.00 to $52.00 and gave the stock an “overweight” rating in a research report on Thursday, March 6th. Raymond James reaffirmed an “outperform” rating and set a $59.00 price objective (up from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Finally, Stifel Nicolaus boosted their price objective on Guardant Health from $53.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, May 1st. Twenty investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $53.29.

Hedge Funds Weigh In On Guardant Health

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Guardant Health by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company’s stock valued at $368,205,000 after purchasing an additional 350,606 shares during the period. Deep Track Capital LP increased its position in shares of Guardant Health by 7.0% during the 4th quarter. Deep Track Capital LP now owns 6,419,566 shares of the company’s stock valued at $196,118,000 after purchasing an additional 419,006 shares during the last quarter. Invesco Ltd. raised its holdings in Guardant Health by 100.9% during the 1st quarter. Invesco Ltd. now owns 2,794,667 shares of the company’s stock valued at $119,053,000 after buying an additional 1,403,670 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Guardant Health by 6.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,777,040 shares of the company’s stock valued at $118,302,000 after buying an additional 164,263 shares during the period. Finally, Two Sigma Advisers LP lifted its position in Guardant Health by 96.7% in the fourth quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company’s stock worth $70,742,000 after buying an additional 1,138,300 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.